Oxford House Residents’ Attitudes Toward Medication Assisted Treatment Use in Fellow Residents
- 242 Downloads
Methadone and buprenorphine/naloxone are medication assisted treatment (MAT) options for treating opioid use disorder, yet attitudes regarding their use within abstinence-based recovery homes have not been assessed. The present investigation examined attitudes regarding MAT utilization among residents living in Oxford Houses. This cross-sectional investigation compared residents (n = 87) receiving MAT whose recent drug use involved opioids, and two groups not receiving MATs; those who had used opioids and those who had used substances other than opioids. The vast majority of residents were not receiving MAT, yet 32% reported MAT histories. Negative attitudes regarding MAT were observed among residents who were not receiving MAT. Those presently receiving MAT reported mixed attitudes regarding the use of methadone and buprenorphine/naloxone, and two of these residents reported they had never been prescribed MAT. Findings suggest that abstinence-based recovery homes such as Oxford Houses may not be optimal resources for persons receiving MATs.
KeywordsMedication assisted treatment Abstinence-based recovery homes Oxford House Methadone Buprenorphine/naloxone Suboxone
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Bretteville-Jensen, A. L., Lillehagen, M., Gjersing, L., & Andreas, J. B. (2015). Illicit use of opioid substitution drugs: prevalence, user characteristics, and the association with non-fatal overdoses. Drug and Alcohol Dependence, 147, 89–96. https://doi.org/10.1016/j.drugalcdep.2014.12.002.CrossRefPubMedGoogle Scholar
- Center for Behavioral Health Statistics and Quality. (2016). Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16-4984, NSDUH Series H-51). Retrieved June 26, 2017, from http://www.samhsa.gov/data/.
- Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-Bartelson, B., & Green, J. L. (2015). Trends in opioid analgesic abuse and mortality in the United States. The New England Journal of Medicine, 372, 241–248. https://doi.org/10.1056/NEJMsa1406143.CrossRefPubMedGoogle Scholar
- Gowing, L., Ali, R., & White, J. M. (2004). Buprenorphine for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews Issue 4. Art. No.: CD002025.pub2. https://doi.org/10.1002/14651858.CD002025.pub4.
- Hill, D. R., Conroy, S., Afzal, A., Lang, D., Steele, S., & Campbell, D. (2015). A comparison of methadone and buprenorphine-naloxone as opioid substitution therapy: The patient perspective in NHS Lanarkshire. Journal of Substance Use, 20, 168–177. https://doi.org/10.3109/14659891.2014.894589.CrossRefGoogle Scholar
- Jason, L. A., Olson, B. D., & Foli, K. (2008). Rescued lives: The Oxford House approach to substance abuse. New York: Routledge.Google Scholar
- Narcotics Anonymous. (2008). Narcotics Anonymous: Basic text (6th edn.). Van Nuys: World Service Office.Google Scholar
- Narcotics Anonymous. (2016). Narcotics Anonymous and persons receiving medication-assisted treatment. Retrieved June 26, 2017, from https://www.na.org/admin/include/spaw2/uploads/pdf/pr/2306_NA_PRMAT_1021.pdf.
- Oxford House Inc. (2011). Oxford House manual. Silver Springs, MD: Oxford House Inc.Google Scholar
- Schwartz, R. P., Kelly, S. M., O’Grady, K. E., Mitchell, S. G., Peterson, J. A., Reisinger, H. S., & Brown, B. S. (2008). Attitudes toward buprenorphine and methadone among opioid-dependent individuals. The American Journal on Addictions, 17, 396–401. https://doi.org/10.1080/10550490802268835.CrossRefPubMedPubMedCentralGoogle Scholar
- Substance Abuse and Mental Health Services Administration. (2011). SAMHSA’s National Registry of Evidence-Based Programs and Practices. Rockville, MD: Author. Retrieved June 26, 2017, from http://www.nrepp.samhsa.gov/ViewIntervention.aspx.